All In Biotech

Drug Trial Radar · NCT06953089

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

A Phase II, Multicenter, Open-Label Trial of DB-1311 in Combination With BNT327 or DB-1305 in Participants With Advanced/Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 750 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

750

Planned (sponsor's estimate)

Start

Jul 18, 2025

Primary completion

Jun 30, 2030

Study completion Jun 30, 2030

Sponsor

Lead sponsor
DualityBio Inc.Industry
Sponsor type
Industry
Collaborators
BioNTech SE
First posted
May 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors

Conditions

  • Solid Tumors

Interventions

  • DB-1311/BNT324Drug

    Administered I.V.

  • BNT327Drug

    Administered I.V.

  • DB-1305/BNT325Drug

    Administered I.V.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of participants with Dose Limiting Toxicities (DLTs).Time frame: During the DLT evaluation period, i.e., the time of initiation of the first dose of investigational medicinal product (IMP) up to 21 days
  2. Part 1: Treatment-emergent adverse events (TEAEs) and treatment-emergent serious AE (TESAEs)Time frame: up to follow up period, e.g. up to 72 months.
  3. Part 2: Objective response rate (ORR), defined as the proportion of participants in whom a confirmed Complete response (CR) or PR is observed as best overall response by arm and dose level. (Arm 1-9).Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months
  4. ORR, defined as the proportion of participants in whom a confirmed CR or PR is observed as best overall response (per PCWG3-modified RECIST v1.1 as assessed by investigator) (Arm 10).Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 72 months

Locations

37 sites in 4 countries. Site status is shown where the registry gives one.

  • USA06-0

    Los Angeles, California · Recruiting

  • USA16-0

    Los Angeles, California · Recruiting

  • USA01-0

    Wheat Ridge, Colorado · Recruiting

  • USA08-0

    Florida City, Florida · Recruiting

  • USA10-0

    Atlanta, Georgia · Recruiting

  • USA11-0

    Bethesda, Maryland · Recruiting

  • USA14-0

    Lincoln, Nebraska · Recruiting

  • USA04-0

    New York, New York · Recruiting

  • USA15-0

    Portland, Oregon · Recruiting

  • USA03-0

    Charleston, South Carolina · Recruiting

  • USA13-0

    Anderson, Texas · Recruiting

  • USA12-0

    Houston, Texas · Recruiting

  • USA05-0

    Virginia Beach, Virginia · Recruiting

  • USA09-0

    Puyallup, Washington · Recruiting

  • USA07-0

    Spokane, Washington · Recruiting

  • AUS07-0

    North Sydney, New South Wales, Australia · Recruiting

  • AUS06-0

    Benowa, Queensland, Australia · Recruiting

  • AUS04-0

    Birtinya, Queensland, Australia · Recruiting

  • AUS05-0

    Adelaide, South Australia, Australia · Recruiting

  • CHN02-0

    Beijing, Beijing Municipality, China · Recruiting

  • CHN13-0

    Beijing, Beijing Municipality, China · Recruiting

  • CHN23-0

    Beijing, Beijing Municipality, China · Recruiting

  • CHN17-0

    Dongguan, Guangdong, China · Recruiting

  • CHN06-0

    Henan, Henan, China · Recruiting

  • CHN12-0

    Xinxiang, Henan, China · Recruiting

  • CHN04-0

    Hubei, Hubei, China · Recruiting

  • CHN26-0

    Wuhan, Hubei, China · Recruiting

  • CHN34-0

    Wuhan, Hubei, China · Recruiting

  • CHN11-0

    Changsha, Hunan, China · Recruiting

  • CHN16-0

    Xuzhou, Jiangsu, China · Recruiting

  • CHN35-0

    Shenyang, Liaoning, China · Recruiting

  • CHN25-0

    Xi'an, Shaanxi, China · Recruiting

  • CHN04-0

    Shanghai, Shanghai Municipality, China · Recruiting

  • CHN01-0

    Shanghai, Shanghai Municipality, China · Recruiting

  • CHN24-0

    Chengdu, Sichuan, China · Recruiting

  • TWN01-0

    Taipei, Taipei, Taiwan · Recruiting

  • TWN02-0

    Taipei, Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.